Taysha gene therapies presents new supplemental data analysis from part a of the reveal phase 1/2 trials for tsha-102 in rett syndrome at the 54th cns annual meeting

Previously disclosed 100% response rate across all 10 patients in part a for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video-evidenced review by independent central raters new supplemental analysis of validated, structured efficacy scales provides supportive evidence of additional functional gains, with 100% of patients demonstrating multiple skill gains/improvements outside the natural history defined developmental milestones findings reinforce the broad and consistent functional gains seen across the core domains that impact activities of daily living, with 22 developmental milestones and 165 additional skills/improvements achieved across the 10 patients post-tsha-102 dallas, oct. 09, 2025 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha) (taysha or the company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (aav)-based gene therapies for severe monogenic diseases of the central nervous system (cns), today announced results from a new supplemental data analysis from part a of the reveal phase 1/2 adult/adolescent and pediatric trials evaluating tsha-102 in females with rett syndrome at the 54th child neurology society (cns) annual meeting. the analysis provides supportive evidence of additional functional gains in skills and improvements across core disease characteristics that are outside of the natural history defined developmental milestones, further highlighting the consistent, multi-domain impact of tsha-102 on activities of daily living.
TSHA Ratings Summary
TSHA Quant Ranking